Square Pharmaceuticals PLC. announcements
313 Dhaka Stock Exchange announcements for Square Pharmaceuticals PLC. (SQURPHARMA) since 2007: results, dividends, board meetings, AGMs, record dates and other price-sensitive information. Showing 2026 (16).
- Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on November 10, 2026 at 3:00 PM to consider, among others, Un-Audited Financial Statements for the First Quarter (Q1) period ended September 30, 2026.
- Dividend Declaration and Others
The Board of Directors has recommended 130% Cash Dividend for the year ended June 30, 2026. Date of AGM: 15.12.2026, Time: 10:00 AM, Venue: Virtual Platform. Record Date: 16.11.2026. The Company has also reported Consolidated EPS of Tk. 31.24, Consolidated NAV per share of Tk. 178.99 and Consolidated NOCFPS of Tk. 18.65 for the year ended June 30, 2026 as against Tk. 27.04, Tk. 157.88 and Tk. 19.52 respectively for the year ended June 30, 2025. (cont.) (Cont. News of SQURPHARMA): The Board of Directors also approved Tk. 725.00 crore for BMRE, Capital Machineries, and Lands for future expansion. (end)
- Price Limit Open
There will be no price limit on the trading of the shares of the Company today (27.10.2026) following its corporate declaration.
- Board Meeting schedule under LR 19(1)
As per Regulation 19(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on October 26, 2026 at 3:00 PM to consider, among others, audited financial statements of the Company for the year ended June 30, 2026.
- Contract Manufacturing Agreement with M/s C2C Pharma Ltd.
The company has informed that the Board of Directors of the company in its meeting held on 28 June 2026 has approved agreements with M/s C2C Pharma Ltd., Dhaka, Bangladesh for contract manufacturing of some products on behalf of Square Pharmaceuticals PLC. to meet increased demand of existing products and to introduce new products. It is mentionable that DSE has requested the company to provide copy of the agreement; however, DSE is yet to receive the copy of the agreement.
- Q3 Financials
(Q3 Un-audited): Consolidated EPS was Tk. 6.73 for January-March 2026 as against Tk. 6.83 for January-March 2025; Consolidated EPS was Tk. 23.29 for July 2025-March 2026 as against Tk. 21.15 for July 2024-March 2025. Consolidated NOCFPS was Tk. 17.54 for July 2025-March 2026 as against Tk. 11.90 for July 2024-March 2025. Consolidated NAV per share was Tk. 169.79 as on March 31, 2026 and Tk. 157.88 as on June 30, 2025. (cont.) (Continuation news of SQURPHARMA): Reasons for Deviation in EPS and NOCFPS: Last year, revenue growth was restrained due to socio-political factors. However, in current year, not only has the business recovered from that slowdown, but it has also experienced a strong upward momentum in revenue performance consequently, both EPS and NOCFPS have recorded notable and healthy growth. (end)
- Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on April 29, 2026 at 3:00 pm to consider, among others, Un-Audited Financial Statements for the Third Quarter (Q3) period ended March 31, 2026.
- Buy Confirmation of Chairman
Mr. Samuel S Chowdhury, Chairman of the Company, has further informed that he has completed his buying of 2,000,000 shares of the company at prevailing market price through Dhaka Stock Exchange PLC. as per declaration disseminated on 20.01.2026.
- Buy Confirmation of Managing Director
Mr. Tapan Chowdhury, Managing Director of the company, has further informed that he has completed his buying of 2,000,000 shares of the company at prevailing market price through Dhaka Stock Exchange PLC. as per declaration disseminated on 5.01.2026.
- Buy Confirmation of a Director
Mrs. Ratna Patra, one of the Directors of the Company, has further informed that she has completed her buying of 1,000,000 shares of the company at prevailing market price through Dhaka Stock Exchange PLC. as per declaration disseminated on 15.01.2026.
- Q2 Financials
(Q2 Un-audited): Consolidated EPS was Tk. 8.20 for October-December 2025 as against Tk. 7.45 for October-December 2024; Consolidated EPS was Tk. 16.56 for July-December 2025 as against Tk. 14.32 for July-December 2024. Consolidated NOCFPS was Tk. 13.16 for July-December 2025 as against Tk. 8.28 for July-December 2024. Consolidated NAV per share was Tk. 162.41 as on December 31, 2025 and Tk. 157.88 as on June 30, 2025. (cont.) (Cont. News of SQURPHARMA): Reasons for deviations: Last year, revenue growth war restrained due to socio-political factors. However, in current year, not only has the business recovered from that slowdown, but it has also experienced a strong upward momentum in revenue performance. Consequently, both EPS and NOCFPS have recorded notable and healthy growth. (end)
- Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on January 29, 2026 at 3:00 PM to consider, among others, Un-Audited Financial Statements for the Second Quarter (Q2) period ended December 31, 2025.
- Dividend Disbursement
The Company has informed that it has disbursed the Cash Dividend for the year ended June 30, 2025 to the respective shareholders.
- Buy Declaration of Chairman
Mr. Samuel S Chowdhury, Chairman of the Company, has expressed his intention to buy 20,00,000 shares of the company at prevailing market price (in the Public and Block Market) through Dhaka Stock Exchange PLC. within next 30 working days.
- Buy Declaration of a Director
Mrs. Ratna Patra, one of the Directors of the Company, has expressed her intention to buy 10,00,000 shares of the company at prevailing market price (in the Public and Block Market) through Dhaka Stock Exchange PLC. within next 30 working days.
- Buy Declaration of Managing Director
Mr. Tapan Chowdhury, Managing Director of the company, has expressed his intention to buy 20,00,000 shares of the company at prevailing market price (in the Public/Block Market) through Dhaka Stock Exchange PLC. within next 30 working days.
Source: Dhaka Stock Exchange announcements. Some posts before 2014 have no title, and 2014–2020 coverage is incomplete.